Creyon Bio

Creyon Bio, Inc. is a biotechnology company revolutionizing the drug development process by focusing on nucleic acid medicine. The company serves pharmaceutical and biotech clients, operating in the drug discovery and development market. Creyon Bio employs a modular approach to create on-demand oligonucleotide therapeutics, which are short DNA or RNA molecules designed to treat specific genetic conditions. This approach significantly reduces the cost and time required to develop new medicines, whether for rare diseases affecting a single patient or widespread conditions impacting millions. The company leverages powerful, purpose-built data sets to drive the creation of machine learning models, enabling the engineering of Medicines OBMs (Oligonucleotide-Based Medicines) with minimal off-target effects. This ensures high precision, efficacy, and safety in gene-centric therapies. Creyon Bio generates revenue through partnerships and collaborations with pharmaceutical companies, offering its advanced drug engineering capabilities to accelerate their drug development pipelines.

Keywords: nucleic acid medicine, oligonucleotide therapeutics, drug engineering, gene-centric therapies, machine learning models, precision medicine, biotechnology, drug discovery, modular approach, pharmaceutical partnerships.